UNSPSC 51203902: Aurotioprol

This classification denotes an antirheumatic agent with the molecular formula C3H6O4S2.Au. Na,, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7097J63E9, chemically known as 1-propanesulfonic acid, 2-hydroxy-3-mercapto-, gold complex but more generally known as aurotioprol, which bears US NIH Compound Identifier 44144564. European Medicines Agency schedules aurotioprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12966MIG.

As of Q4 2014, AUROTIOPROL remains US FDA's Preferred Term for this commodity. SMILES: C(C(CS(=O)(=O)O)O)S.[Na+].[Au+].

UNSPSC 51203902 Aurotioprol, a Commodity code, does not reflect the actual work being solicited under recent state and local contract opportunities tagged to this code. The four recent solicitations—from Seminole County (Florida), the Texas Health and Human Services Commission, the City of Tampa, and the Minnesota Multistate Cooperative Purchasing Alliance—involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency responders, and generic pharmaceuticals and over-the-counter products. None of these procurements concern aurotioprol as a pharmaceutical agent. The code shows little relevant recent activity aligned with its nominal scope, and the opportunities posted under it represent a significant mismatch between the UNSPSC taxonomy label and the goods actually being purchased.

State and local issuing bodies—including county health departments, state health and human services commissions, municipal fire departments, and multi-state cooperative purchasing alliances—are actively procuring naloxone, emergency medical supplies, and generic pharmaceuticals through IFBs, RFPs, RFIs, and cooperative-purchasing vehicles. The geographic spread includes Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB (due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually; the City of Tampa's IFB (due March 13, 2026) for medical and first aid supplies to the Fire Department Rescue Division, estimated at $700,000 and reserved for certified Small Local Business Enterprises; and MMCAP's RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities. Given the taxonomy mismatch, this code warrants close review before pursuing opportunities posted under it.